Hagop M Kantarjian

298PUBLICATIONS
430CO-AUTHORS
Gene and molecular therapyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical virologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (298)

|Jul 06, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

|Jul 04, 2026
Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Jun 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

|Jun 11, 2026
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

|Jun 01, 2026
Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring.

Pageof 50

Frequent Collaborators

167 joint publications

Elias Jabbour

141 joint publications

Tapan M Kadia

122 joint publications

Navel G Daver

118 joint publications

Courtney DiNardo